Araştırma Makalesi
BibTex RIS Kaynak Göster

Incidence of Kidney Stones in Inpatients in Intensive Care

Yıl 2022, Cilt: 19 Sayı: 2, 295 - 300, 28.08.2022
https://doi.org/10.35440/hutfd.1121971

Öz

Background: The aim of this study is to examine the incidence of kidney stones, mortality status, length of stay in the intensive care unit and length of hospitalization according to the gender and age of the patients hospitalized in the intensive care unit.
Materials and Methods: This study was designed as a retrospective cross-sectional study. Between 2020-2021, Health Sciences University Sanliurfa Mehmet Akif İnan Education Research Hospital was carried out with 376 patients between the ages of 10-94 who applied to the hospital. In the scope of the study, gender, age, renal stone or cyst status as a result of imaging, mortality status, duration of intensive care hospitalization, and hospitalization period of the patients were recorded. Data were analyzed using Chi-square, ANOVA and independent t-test.
Results: According to the findings, the overall incidence of kidney stones in the patients participa-ting in this study was found to be 7%. In this study, when the incidence of kidney stones in fema-le and male patients was examined, it was found as 6% in female patients and 8% in male pati-ents. However, this difference was not statistically significant. It has also been understood that the incidence of kidney stones increases with age. The mortality rate of those with kidney stones was found to be 2%.
Conclusions: The findings obtained at the end of this study show parallels with the literature. Due to the different geography and patient profile of the study, the existing data were suppor-ted by different demographic data.


Kaynakça

  • 1-Narter F, Sarıca K. Üriner Sistem Taş Hastalığının Biyomoleküler Mekanizması. Enduüroloji Bülteni, 2013;6:135-142.
  • 2-Parmar MS. Kidneystones BMJ, 2004; 328 :1420 doi:10.1136/bmj.328.7453.1420.
  • 3-NouriAI, HassaliMA. Assessment of kidney stone disease prevalence in a teaching hospital African Journal of Urology, 2018; 24(3);180-185.
  • 4- Sohgaura A, Bigoniya P. A Review on Epidemiology and Etiology of Renal Stone. Am J DrugDiscov Dev. 2017 Mar 15;7(2):54–62.
  • 5- Evan AP, Lingeman JE, Coe FL, Parks JH, Bledsoe SB, Shao Y, et al. Randall’s plaque of patients with nephrolithiasis begins in basement membranes of thin loops of Henle. J Clin Invest. 2003 Mar 1;111(5):607–16.
  • 6- Goddard J, Turner AN.Kidney and urinarytract diseases. In: Walker, B.R.,Colledge, N.R., Ralston, S.H., Penman, I. (eds.). Davidson’sprinciples and practice of medicine (22nd ed.) (pp 461–524). Edinburgh: Churchill Livingstone. 2014.
  • 7- Ötüntemur A,Beşiroğlu H, Dursun M, Şahin S, Köklü İ, Erkoç M, Danış E, Bozkurt M, Özbek E. Açık Böbrek Cerrahisi Geçiren Hastalarda Perkütan Nefrolitotominin Güvenilirliği ve Etkinliği 2013;29(3).
  • 8- Joel M H Teichman Clinical practice. Acute renal colic from ureteral calculus N Engl J Med. 2004 Feb 12;350(7):684-93. doi: 10.1056/NEJMcp030813
  • 9- Chewcharat A, Curhan G. Trends in the prevalence of kidney stones in the United States from 2007 to 2016. Urolithiasis. 2021 Feb 1;49(1):27–39.
  • 10- RuleAD, Bergstralh EJ,Melton LJ,Li X,Weaver AL,LieskeJC. Kidney Stones and the risk for chronic kidney diseaseClin J Am SocNephrol, 2009;4 (4): 804-811.
  • 11- Donnally CJ,Gupta A,BensalahK, TuncelA, Raman J,Pearle, MS.et al. Longitudinalevaluation of the SF-36 quality of life questionnaire in patientswithkidney Stones UrolRes, 2011;39 (2): 141-146.
  • 12- Mutlu N,Özkan L, Duman C, Eralp MKM, Meral H, Gökalp A: Tekrarlayıcı taş hastalığı olanlarda metabolik değerlendirme sonuçları. Türk Üroloji Dergisi, 2004;30(2): 230- 234.
  • 13- Uribari J,Oh MS, Carroll HJ: Thefirstkidney Stone. Annintern Med 1989;111:1006– 1009.
  • 14- Adayener C. et al.,The evaluation of biochemical risk factors for recurrenturinary stone disease. Turkish Journal of Urology, 2007. 33:205-212.
  • 15- Adayener, C., et al., The evaluation of biochemical risk factors for recurrent urinary stone disease. Turkish Journal of Urology, 2007. 33: p. 205-212.
  • 16- Romero V, Akpinar H, Assimos DG. Reviews in Urology Disease State Review. RevUrol 2010;12(2):86-96.
  • 17- Scales CD Jr, Smith AC, Hanley JM et al: Prevalence of kidney stones in the United States. EurUrol 2012; 62: 160. 18- Türk, C., et al., EAU guidelines on interventional treatment for urolithiasis. Europeanurology, 2016. 69(3): 475-482.
  • 19- Curhan GC, Willet WC, Rimm EB, Stampfer MJ: Family history and risk of kidney Stones. J Am SocNephrol 1997;8,1568–1573.
  • 20- Akinci M, Esen T, Tellaloglu S.Urinarystone disease in Turkey: an update depidemiological study. EurUrol, 1991; 20(3): 200-3.
  • 21- Muslumanoglu AY, Binbay M, Yuruk E, Akman T, Tepeler A, Esen T, et al. Updated epidemiologic study of urolithiasis in Turkey. I: Changing characteristics of urolithiasis. Urological research, 2011;39(4):309-14.
  • 22- Leusmann DB, Michels M. Has there been a change in stone composition during the past 20 years. In Book of Proceedings 9th International Symposium on Urolithiasis 2000:362- 65.
  • 23- Önen A. Çocuklarda üriner sistem taş hastalığı. Çocuk Cerrahisi Dergisi 2013;27(1):8-32.
  • 24- Sorokin I, Mamoulakis C, Miyazawa K, Rodgers A, Talati J, Lotan Y. Epidemiology of stone diseasea cross the world. World J Urol. 2017;35(9):1301–20.
  • 25-Soucie JM, Thun MJ, Coates RJ, et al. Demographic and geographic variability of kidney stones in the United States. KidneyInt. 1994;46:893–899.
  • 26-Sánchez-Martín FM, MillánRodríguez F, Esquena Fernández S, et al. Incidence and prevalence of published studies abouturolithiasis in Spain: a review ActasUrolEsp. 2007;31:511–520.
  • 27-Scott R, Freeland R, Mowat W, et al. The prevalence of calcified upper urinarytract stone disease in a random population-Cumbernauld Health Survey. Br J Urol. 1977;49:589–595.
  • 28- Stoller, M., et al., Üriner taş hastalığı. Çeviri: Kazancı G. Smith Genel Üroloji. Nobel Tıp Kitabevleri Ltd. Şti, 1999: p. 276-30.
  • 29-Teklehaimanot SZ,Bahta B, Baye NK, et al. Prevalence of Kidney Stones Among Patients Presenting to Orotta Medical Surgical National Referral Hospital, 29 December 2021.
  • 30-Alexander RT, Hemmelgarn BR, Wiebe N, Bello A, Morgan C, Samuel S et al. Kidney Stones and kidney function loss: a cohort study BMJ 2012; 345 :e5287 doi:10.1136/bmj.e5287.
  • 31- Nowfar, S., et al., The relationship of obesity and gender prevalence changes in United States in patientnephrolithiasis.Urology, 2011. 78(5): 1029-1033.
  • 32- Robert H,Gregory J,Barton, Anai N. Kothari, Matthew A.C. Zapf, Robert C. Flanigan, Paul C. Kuo, Gopal N. Gupta. EarlyIntervention during Acute Stone Admissions: Revealing “The Weekend Effect” in Urological Practice. The Journal of Urology, 2016; DOI: 10.1016/j.juro.2016.01.056.

Yoğun Bakımda Yatan Hastalarda Böbrek Taşı İnsidansı

Yıl 2022, Cilt: 19 Sayı: 2, 295 - 300, 28.08.2022
https://doi.org/10.35440/hutfd.1121971

Öz

Amaç:Bu çalışmanın amacı; yoğun bakım ünitesinde yatan hastaların cinsiyetine ve yaşına göre böbrek taşı insidansı, mortalite durumları, yoğun bakım yatış süreleri ve hastane yatış sürelerini incelemektir.
Materyal ve Metod: Bu çalışma retrospektif kesitsel bir çalışma tasarımı olarak yapılmıştır. 2020-2021 tarihleri arasında Sağlık Bilimleri Üniversitesi Şanlıurfa Mehmet Akif İnan SUAM Cerrahi Yoğun Bakım Ünitesi ve Üroloji Kliniği tarafından 10-94 yaş arası yoğun bakım ünitesine yatan 376 hasta ile gerçekleştirilmiştir. Çalışma kapsamına hastaların cinsiyet, yaş, görüntüleme sonuncunda böbrek taş veya kist durumu, mortalite durumu, yoğun bakım yatış süresi, hastane yatış süresi kayıt edilmiştir. Veriler Ki-kare, ANOVA ve bağımsız t-test kullanılarak analiz edilmiştir.
Bulgular: Elde edilen bulgulara göre bu çalışmaya katılan hastaların böbrek taşı genel insidansı %7,38 olarak bulunmuştur. Bu çalışma kapsamında kadın hastaların ve erkek hastaların böbrek taşı insidansı incelendiğinde kadın hastalarda %6,45 olarak bulunurken erkek hastalarda %7,60 olarak bulunmuştur. Ancak bu farklılık istatiksel olarak anlamlı bulunmamıştır. Ayrıca yaş ile birlikte böbrek taşı insidansının yükseldiği anlaşılmıştır. Böbrek taşı olanların ölüm oranı %1,9 olarak bulunmuştur.
Sonuçlar: Bu çalışma sonunda elde edilen bulgular literatür ile paralellikler göstermektedir. Çalışmanın uygulandığı coğrafyanın ve hasta profilinin farklı olmasından dolayı mevcut verilerin farklı demografik yapı verileri ile desteklenmesi sağlanmıştır.

Kaynakça

  • 1-Narter F, Sarıca K. Üriner Sistem Taş Hastalığının Biyomoleküler Mekanizması. Enduüroloji Bülteni, 2013;6:135-142.
  • 2-Parmar MS. Kidneystones BMJ, 2004; 328 :1420 doi:10.1136/bmj.328.7453.1420.
  • 3-NouriAI, HassaliMA. Assessment of kidney stone disease prevalence in a teaching hospital African Journal of Urology, 2018; 24(3);180-185.
  • 4- Sohgaura A, Bigoniya P. A Review on Epidemiology and Etiology of Renal Stone. Am J DrugDiscov Dev. 2017 Mar 15;7(2):54–62.
  • 5- Evan AP, Lingeman JE, Coe FL, Parks JH, Bledsoe SB, Shao Y, et al. Randall’s plaque of patients with nephrolithiasis begins in basement membranes of thin loops of Henle. J Clin Invest. 2003 Mar 1;111(5):607–16.
  • 6- Goddard J, Turner AN.Kidney and urinarytract diseases. In: Walker, B.R.,Colledge, N.R., Ralston, S.H., Penman, I. (eds.). Davidson’sprinciples and practice of medicine (22nd ed.) (pp 461–524). Edinburgh: Churchill Livingstone. 2014.
  • 7- Ötüntemur A,Beşiroğlu H, Dursun M, Şahin S, Köklü İ, Erkoç M, Danış E, Bozkurt M, Özbek E. Açık Böbrek Cerrahisi Geçiren Hastalarda Perkütan Nefrolitotominin Güvenilirliği ve Etkinliği 2013;29(3).
  • 8- Joel M H Teichman Clinical practice. Acute renal colic from ureteral calculus N Engl J Med. 2004 Feb 12;350(7):684-93. doi: 10.1056/NEJMcp030813
  • 9- Chewcharat A, Curhan G. Trends in the prevalence of kidney stones in the United States from 2007 to 2016. Urolithiasis. 2021 Feb 1;49(1):27–39.
  • 10- RuleAD, Bergstralh EJ,Melton LJ,Li X,Weaver AL,LieskeJC. Kidney Stones and the risk for chronic kidney diseaseClin J Am SocNephrol, 2009;4 (4): 804-811.
  • 11- Donnally CJ,Gupta A,BensalahK, TuncelA, Raman J,Pearle, MS.et al. Longitudinalevaluation of the SF-36 quality of life questionnaire in patientswithkidney Stones UrolRes, 2011;39 (2): 141-146.
  • 12- Mutlu N,Özkan L, Duman C, Eralp MKM, Meral H, Gökalp A: Tekrarlayıcı taş hastalığı olanlarda metabolik değerlendirme sonuçları. Türk Üroloji Dergisi, 2004;30(2): 230- 234.
  • 13- Uribari J,Oh MS, Carroll HJ: Thefirstkidney Stone. Annintern Med 1989;111:1006– 1009.
  • 14- Adayener C. et al.,The evaluation of biochemical risk factors for recurrenturinary stone disease. Turkish Journal of Urology, 2007. 33:205-212.
  • 15- Adayener, C., et al., The evaluation of biochemical risk factors for recurrent urinary stone disease. Turkish Journal of Urology, 2007. 33: p. 205-212.
  • 16- Romero V, Akpinar H, Assimos DG. Reviews in Urology Disease State Review. RevUrol 2010;12(2):86-96.
  • 17- Scales CD Jr, Smith AC, Hanley JM et al: Prevalence of kidney stones in the United States. EurUrol 2012; 62: 160. 18- Türk, C., et al., EAU guidelines on interventional treatment for urolithiasis. Europeanurology, 2016. 69(3): 475-482.
  • 19- Curhan GC, Willet WC, Rimm EB, Stampfer MJ: Family history and risk of kidney Stones. J Am SocNephrol 1997;8,1568–1573.
  • 20- Akinci M, Esen T, Tellaloglu S.Urinarystone disease in Turkey: an update depidemiological study. EurUrol, 1991; 20(3): 200-3.
  • 21- Muslumanoglu AY, Binbay M, Yuruk E, Akman T, Tepeler A, Esen T, et al. Updated epidemiologic study of urolithiasis in Turkey. I: Changing characteristics of urolithiasis. Urological research, 2011;39(4):309-14.
  • 22- Leusmann DB, Michels M. Has there been a change in stone composition during the past 20 years. In Book of Proceedings 9th International Symposium on Urolithiasis 2000:362- 65.
  • 23- Önen A. Çocuklarda üriner sistem taş hastalığı. Çocuk Cerrahisi Dergisi 2013;27(1):8-32.
  • 24- Sorokin I, Mamoulakis C, Miyazawa K, Rodgers A, Talati J, Lotan Y. Epidemiology of stone diseasea cross the world. World J Urol. 2017;35(9):1301–20.
  • 25-Soucie JM, Thun MJ, Coates RJ, et al. Demographic and geographic variability of kidney stones in the United States. KidneyInt. 1994;46:893–899.
  • 26-Sánchez-Martín FM, MillánRodríguez F, Esquena Fernández S, et al. Incidence and prevalence of published studies abouturolithiasis in Spain: a review ActasUrolEsp. 2007;31:511–520.
  • 27-Scott R, Freeland R, Mowat W, et al. The prevalence of calcified upper urinarytract stone disease in a random population-Cumbernauld Health Survey. Br J Urol. 1977;49:589–595.
  • 28- Stoller, M., et al., Üriner taş hastalığı. Çeviri: Kazancı G. Smith Genel Üroloji. Nobel Tıp Kitabevleri Ltd. Şti, 1999: p. 276-30.
  • 29-Teklehaimanot SZ,Bahta B, Baye NK, et al. Prevalence of Kidney Stones Among Patients Presenting to Orotta Medical Surgical National Referral Hospital, 29 December 2021.
  • 30-Alexander RT, Hemmelgarn BR, Wiebe N, Bello A, Morgan C, Samuel S et al. Kidney Stones and kidney function loss: a cohort study BMJ 2012; 345 :e5287 doi:10.1136/bmj.e5287.
  • 31- Nowfar, S., et al., The relationship of obesity and gender prevalence changes in United States in patientnephrolithiasis.Urology, 2011. 78(5): 1029-1033.
  • 32- Robert H,Gregory J,Barton, Anai N. Kothari, Matthew A.C. Zapf, Robert C. Flanigan, Paul C. Kuo, Gopal N. Gupta. EarlyIntervention during Acute Stone Admissions: Revealing “The Weekend Effect” in Urological Practice. The Journal of Urology, 2016; DOI: 10.1016/j.juro.2016.01.056.
Toplam 31 adet kaynakça vardır.

Ayrıntılar

Birincil Dil Türkçe
Konular Klinik Tıp Bilimleri
Bölüm Araştırma Makalesi
Yazarlar

Halil Ferat Öncel 0000-0003-4043-5597

Firdevs Tugba Bozkurt 0000-0002-1461-5933

Yayımlanma Tarihi 28 Ağustos 2022
Gönderilme Tarihi 26 Mayıs 2022
Kabul Tarihi 13 Haziran 2022
Yayımlandığı Sayı Yıl 2022 Cilt: 19 Sayı: 2

Kaynak Göster

Vancouver Öncel HF, Bozkurt FT. Yoğun Bakımda Yatan Hastalarda Böbrek Taşı İnsidansı. Harran Üniversitesi Tıp Fakültesi Dergisi. 2022;19(2):295-300.

Harran Üniversitesi Tıp Fakültesi Dergisi  / Journal of Harran University Medical Faculty